#AstraZenecaVaccine, #79percentEfficatyInPreventingCovid19; #Canada; #US #100percentPreventsSevereDiseaseHospitalization;
New York/Canadian-Media: Advanced trial data on its AstraZeneca coronavirus vaccine from a U.S. study showed 79 percent effectiveness of the vaccine at preventing symptomatic COVID-19, and 100 percent effective in halting severe disease and hospitalization, said AstraZeneca in a statement this morning.
AstraZeneca Covid19 vaccine. Image credit: Wikimedia commons
The effectiveness of the vaccine across adults of all ages including older people was reported by the investigators, which other countries with previous studies had failed to establish.
"These findings reconfirm previous results observed," said Ann Falsey of the University of Rochester School of Medicine, who helped lead the trial. "It's exciting to see similar efficacy results in people over 65 for the first time," CBC News reported.
Also, no safety concerns related to the vaccine were identified by AstraZeneca's experts, including a rare blood clot that was identified in Europe.
It was found by the scientists that there was no increased risk of clots among the more than 20,000 people who got at least one dose of the shot, which was developed with Oxford University.
Although the vaccine has been approved for use in 50 countries, including Canada, it has not yet been approved in the U.S.
Canada is expected to receive 1.5 million doses of the AstraZeneca-Oxford product from the U.S. government perhaps as early as this week.